Join us at #EBMT24 “Immunotherapy joining forces with ASCT in myeloma: the IFM perspective” -Sunday, April 14 at 08:30 am -A non-profit session held since 10 years at the Annual Meeting of ⁦@TheEBMT⁩ Chaired by JL Harousseau - Hall 5- Scottish Event Campus ⁦⁦

A great start for the new year with the launch of the first MEMAC meeting! Thank you all for your support to make this event possible. @TheIACH @SSBMT @AUBMC_Official @MKD_BMT @shahrukhhashmi @COMyCongress

Congress #EBMT23 | @shahrukhhashmi & @BipinSavani discusses on how to prevent the complications of chronic #GvHD. The talk emphasizes on recognizing #chronicGvHD, diagnostic testing, choice of prophylaxis regimen, and cost-effective treatment strategy. #bmtsm #medicalcongress

Ending the day with a case discussion forum ! #EBMT23 @shahrukhhashmi @Florent_Malard @docgiorgicchia @OlaOluwole4

Live from #EBMT23. Thank you all for joining. What a great transplant community ⁦@TheEBMT⁩ ⁦@TheEBMT_Nurses⁩ ⁦@TheIACH⁩

Remarkable clinical care advances are possible through incredible collaborative efforts of the COOP and network groups. Congratulations @MRLitzow @sghmd for practice changing #ASH22 LBA presentations! @shahrukhhashmi @DrMiguelPerales @MayoCancerCare @BMTCTN @eaonc

@szusmani @ASTCT @HemOncFellows Grateful for your support and humbled by the nomination by @ASTCT leadership

Debate: Auto vs Allo #CART at 2nd Hematology Masterclass #Dubai moderated by @shahrukhhashmi auto is here to stay for now. Many challenges to overcome for allo: technology, donor source, lymphodepletion. Tune in next year…@mustaqeemS @MayoCancerCare @MayoRegMed

@nagler_EBMT presents outcome for #Isreal academic center #CART manufacturing at 2nd Hematology Masterclass in #Dubai another model of access for patients. We need regulatory pathway for these to get into SOC practice. @mustaqeemS @shahrukhhashmi @MayoCancerCare @MayoRegMed

Gene and cell therapy move into non-malignant indications. Great scientific advance. Dr. Stephan Grupp @UPennCancer shares at 2nd Hematology Masterclass #Dubai. But they make #CART seem cheap by comparison. @mustaqeemS @shahrukhhashmi @MayoRegMed @MayoHemeOnc

Dr. Syed Osman Ahmed @KFSHRC presents on building a #CART program at 2nd Hematology Masterclass: offering hope while maintaining financial sustainability. Practical considerations globally! @mustaqeemS @shahrukhhashmi @MayoCancerCare @MayoRegMed

Day 2 of 2nd Hematology Masterclass, inspiring speech by Dr. Asma Ibrahim Al Mannaei at DoH #AbudhabiGovernment “We cannot wait for innovations to come to us”. @shahrukhhashmi moderating future ecosystem of research in #UAE @MayoCancerCare @MayoRegMed @mustaqeemS

Esteemed Dr. Partow Kebriaei @MDAndersonNews present #CART in #leuksm at 2nd Hematology Masterclass: first approved indication, real world data to drive future directions @mustaqeemS @shahrukhhashmi @MayoCancerCare @MayoRegMed

Jet lags aside, looking forward to a very exciting agenda to the 2nd Hematology Masterclass! @mustaqeemS @shahrukhhashmi organized deep dive to cell therapy, & effort to expand access in #UAE @MayoCancerCare @MayoRegMed #mmsm #leuksm #lymsm

#BMTsm HSCT abstract review @ASHLiveReviewPK @shahrukhhashmi https://t.co/Z4xvoE3czW @ASH_hematology

ASTCT Committee Practice Guidelines on Management of DLBCL after CAR T failure #BMTsm @ASTCT @ASTCT_Journal @NausheenAhmedMD @MediHumdani @DrMiguelPerales @shahrukhhashmi

Think we evaluate and manage CAR-T failures in DLBCL uniformly? Hot off the press @ASTCT survey sheds light on real life practice @ASTCT_Journal by @NausheenAhmedMD @MKD_BMT @DrMiguelPerales @DholariaMD @DrZackDeFilipp @shahrukhhashmi #lymsm #CART 6/1 https://t.co/HdtACmYpjh

@GruppSteve @FDA Celebrating 10 years. We are so grateful for the brave patients who volunteered for CAR T at CHOP and PennMedicine

Eid Mubarak #MedTwitter family. To you and yours.